Life sciences and biopharma companies often rely on clinical trial results and "clinically proven effective" language in patent claims, but this approach carries significant risks if key details are publicly disclosed before...more
10/2/2025
/ Bayer ,
CAFC ,
Clinical Trials ,
Life Sciences ,
Mylan Pharmaceuticals ,
Obviousness ,
Patent Applications ,
Patent Invalidity ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prior Art
We have published other blog postings relating to 35 U.S.C. §325(d), including a blog posting that addresses the PTAB’s October 24, 2017 notice designating three of its decisions as informative (here). Recently, the PTAB...more
On February 28, 2017, the PTAB held that the petitioner Lupin had not shown that the challenged claims in two of Pozen’s patents were invalid (IPR2015-01773 and IPR2015-01775). These cases show the advantage of using...more